242 related articles for article (PubMed ID: 21425126)
1. The dense fine speckled antinuclear antibody pattern in autoimmune rheumatic disease: comment on the article by Mariz et al.
Craig WY; Ledue TB
Arthritis Rheum; 2011 Jun; 63(6):1759; author reply 1760. PubMed ID: 21425126
[No Abstract] [Full Text] [Related]
2. Recognizing the dense fine speckled/lens epithelium-derived growth factor/p75 pattern on HEP-2 cells: not an easy task! Comment on the article by Mariz et al.
Bizzaro N; Tonutti E; Villalta D
Arthritis Rheum; 2011 Dec; 63(12):4036-7; author reply 4037-8. PubMed ID: 22127717
[No Abstract] [Full Text] [Related]
3. [Importance of the dense fine speckled pattern and anti-DFS70 antibodies for the diagnosis of systemic autoimmune rheumatic diseases].
López Sañudo S; Fernández Alonso I; López Hoyos M
Med Clin (Barc); 2015 Sep; 145(5):218-23. PubMed ID: 26021571
[No Abstract] [Full Text] [Related]
4. Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases.
Mariz HA; Sato EI; Barbosa SH; Rodrigues SH; Dellavance A; Andrade LE
Arthritis Rheum; 2011 Jan; 63(1):191-200. PubMed ID: 20954189
[TBL] [Abstract][Full Text] [Related]
5. The antinuclear antibody dense fine speckled pattern and possible clinical associations: An indication of a proinflammatory microenvironment.
Lundgren MC; Sapkota S; Peterson DJ; Crosson JT
J Immunol Methods; 2021 Jan; 488():112904. PubMed ID: 33121975
[TBL] [Abstract][Full Text] [Related]
6. Dense fine speckled indirect immunofluorescence pattern in an Australian population.
Broadfoot A; Sivertsen T; Baumgart K
Pathology; 2016 Apr; 48(3):247-50. PubMed ID: 27020500
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of anti-dense fine speckled 70 antibodies in healthy individuals and patients with antinuclear antibody-associated autoimmune rheumatic diseases in Japan.
Hayashi N; Uto K; Imanishi A; Sugiyama D; Morinobu A; Saegusa J
Medicine (Baltimore); 2021 Mar; 100(9):e24556. PubMed ID: 33655922
[TBL] [Abstract][Full Text] [Related]
8. Are we at a stage to predict autoimmune rheumatic diseases?
Bizzaro N; Tozzoli R; Shoenfeld Y
Arthritis Rheum; 2007 Jun; 56(6):1736-44. PubMed ID: 17530702
[No Abstract] [Full Text] [Related]
9. [The spectrum of antinuclear and anticytoplasmatic antibodies in collagenoses].
Meurer M; Ring J
Hautarzt; 1980 Sep; 31(9):478-85. PubMed ID: 6969717
[TBL] [Abstract][Full Text] [Related]
10. The antinuclear antibody test: last or lasting gasp?
Fritzler MJ
Arthritis Rheum; 2011 Jan; 63(1):19-22. PubMed ID: 20954183
[No Abstract] [Full Text] [Related]
11. Harmonization of autoimmune diagnostics with antinuclear antibody testing algorithm: approach of appropriateness and clinical relevance.
Melegari A; Bonaguri C
Isr Med Assoc J; 2014 Oct; 16(10):640-2. PubMed ID: 25438456
[No Abstract] [Full Text] [Related]
12. Detection of anti-nuclear antibodies by indirect immunofluorescence on HEp-2 cells: setting the appropriate screening dilution for the diagnosis of autoimmune rheumatic diseases.
Brito Fde A; Santos SM; Ferreira GA; Pedrosa W; Gradisse J; Costa LC; Neves SP
Rev Bras Reumatol; 2014; 54(1):13-20. PubMed ID: 24878786
[TBL] [Abstract][Full Text] [Related]
13. How to use... antinuclear antibodies in paediatric rheumatic diseases.
Weaver LK; Behrens EM
Arch Dis Child Educ Pract Ed; 2013 Apr; 98(2):64-70. PubMed ID: 23492397
[No Abstract] [Full Text] [Related]
14. The association of solid-phase assays to immunofluorescence increases the diagnostic accuracy for ANA screening in patients with autoimmune rheumatic diseases.
Bizzaro N; Brusca I; Previtali G; Alessio MG; Daves M; Platzgummer S; Cinquanta L; Paura G; Infantino M; Manfredi M; Faricelli R; Bassetti D; Musso M; Deleonardi G; Trevisan MT; Radice A; Liguori M; Imbastaro T; Pesente F; Fabris M; Tonutti E
Autoimmun Rev; 2018 Jun; 17(6):541-547. PubMed ID: 29631063
[No Abstract] [Full Text] [Related]
15. Understanding and interpreting antinuclear antibody tests in systemic rheumatic diseases.
Bossuyt X; De Langhe E; Borghi MO; Meroni PL
Nat Rev Rheumatol; 2020 Dec; 16(12):715-726. PubMed ID: 33154583
[TBL] [Abstract][Full Text] [Related]
16. Anti-telomere antibodies in systemic lupus erythematosus (SLE): a comparison with five antinuclear antibody assays in 430 patients with SLE and other rheumatic diseases.
Salonen EM; Miettinen A; Walle TK; Koskenmies S; Kere J; Julkunen H
Ann Rheum Dis; 2004 Oct; 63(10):1250-4. PubMed ID: 15361381
[TBL] [Abstract][Full Text] [Related]
17. Application of a combined protocol for rational request and utilization of antibody assays improves clinical diagnostic efficacy in autoimmune rheumatic disease.
Tampoia M; Brescia V; Fontana A; Zucano A; Morrone LF; Pansini N
Arch Pathol Lab Med; 2007 Jan; 131(1):112-6. PubMed ID: 17227110
[TBL] [Abstract][Full Text] [Related]
18. High concomitance of disease marker autoantibodies in anti-DFS70/LEDGF autoantibody-positive patients with autoimmune rheumatic disease.
Muro Y; Sugiura K; Morita Y; Tomita Y
Lupus; 2008 Mar; 17(3):171-6. PubMed ID: 18372356
[TBL] [Abstract][Full Text] [Related]
19. Determination of Specificity and Pattern of Antinuclear Antibodies (ANA) in Systemic Rheumatic Disease Patients Positive for ANA Testing.
Tipu HN; Bashir MM
J Coll Physicians Surg Pak; 2018 Jan; 28(1):40-43. PubMed ID: 29290190
[TBL] [Abstract][Full Text] [Related]
20. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing.
Solomon DH; Kavanaugh AJ; Schur PH;
Arthritis Rheum; 2002 Aug; 47(4):434-44. PubMed ID: 12209492
[No Abstract] [Full Text] [Related]
[Next] [New Search]
